The Food and Drug Administration (FDA) is announcing a public workshop entitled “Medical Countermeasures (MCM) for a Burn Mass Casualty Incident.” This workshop will engage stakeholders across the public and private sector in strategic dialogue related to development, evaluation, deployment and monitoring of medical countermeasures to mitigate the adverse health consequences arising from public health emergencies, specifically those involving radiological, nuclear or chemical threats. The focus of this workshop is on management of the burn injury, bringing together cross-disciplinary subject matter experts to - discuss unmet needs; underscore issues related to product development, testing and commercialization; and address opportunities to meet those challenges leveraging coordination and collaboration among strategic networks.
The purpose of this workshop is to - describe medical countermeasure requirements for burn injuries of radiological, nuclear or chemical origin in a ‘scarce resources’ environment; identify gaps in the product landscape so as to articulate a consensus-based needs assessment; discuss testing approaches and regulatory pathways; and to educate workshop attendees on the concept of medical utilization and response integration.
This workshop will be held September 27, 2012 and September 28, 2012, at the following location:
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center (Great Room, Section A)
Silver Spring, MD 20993
The workshop will be webcasted. (details to register for the webcast will be available soon)
To Be Announced
CALL FOR POSTERS - This workshop will include a poster session. Please indicate if you wish to present an abstract during the poster session by email to Suzanne Schwartz MD, MBA (Suzanne.Schwartz@fda.hhs.gov ). Abstracts should be submitted by email no later than 5:00 PM on August 31, 2012. No commercial promotional material will be permitted to be presented or distributed at the public workshop.
Registration for this workshop will be available soon.
For questions regarding workshop content and abstract submission, please contact:
Suzanne Schwartz MD, MBA
Food and Drug Administration
10903 New Hampshire Ave, Silver Spring, MD 20993
email: Suzanne.Schwartz@fda.hhs.gov